Tel Aviv, Israel, June 7 (Korea Bizwire) – Following US Food and Drug Administration (FDA) clearance of the MeMed BV® test, which helps physicians distinguish between bacterial and viral infections in just 15 minutes, Maccabi Healthcare Services announces today it is launching the test in all its urgent care centers around Israel. Maccabi is one of the largest [...]
HAIFA, Israel; BOSTON, MA, Jan. 10 (Korea Bizwire) – MeMed, a leader in host response technologies, today announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and [...]
HAIFA, Israel, Boston, MA; Sept. 20 (Korea Bizwire) – MeMed, a leader in the emerging field of advanced host-response technologies, today announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on the point-of-need platform MeMed Key® to help healthcare providers distinguish between bacterial and viral infections. [...]
HAIFA, Israel, July 23 (Korea Bizwire) — Researchers at Israel’s Rabin Medical Center (comprised of Beilinson and Hasharon Hospitals) in collaboration with MeMed, have published prospective data on the potential utility of the analysis of IP-10, a host immune biomarker, in managing the care and treatment of patients with severe COVID-19 infection. Initial data from the prospective study shows that continuous and rapid measurements of IP-10, a biomarker associated with inflammatory disease including infectious diseases and immune dysfunction, can [...]